vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
24 mai 2023 09h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for...
vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update
11 mai 2023 16h15 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for...
vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
06 mars 2023 17h56 HE
|
vTv Therapeutics Inc.
Company preparing to initiate Phase 3 clinical trials of TTP399, an adjunctive therapy to insulin, for the treatment of Type 1 diabetesBiotech industry and Wall Street veteran Steven Tuch appointed...
Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
01 févr. 2023 17h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
13 déc. 2022 08h15 HE
|
vTv Therapeutics Inc.
Steven Tuch, Chief Financial Officer HIGH POINT, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the...
vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update
10 nov. 2022 17h25 HE
|
vTv Therapeutics Inc.
Company on-track to initiate Phase 3 clinical trials of TTP399 in the first quarter of 2023 Industry veteran Paul Sekhri joins the Company as President, Chief Executive Officer, and member of the...
vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update
15 août 2022 18h43 HE
|
vTv Therapeutics Inc.
Paul Sekhri appointed as President, Chief Executive Officer and Board member. Entered into agreements with CinRx Pharma and a subsidiary to purchase $10 million in stock and to leverage CinRx’s...
vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer
27 juil. 2022 07h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Therapeutics Announces Investment by CinRx Pharma
25 juil. 2022 07h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (“CinPax”), a...
vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
04 juin 2022 11h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., June 04, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for...